Please assess the completion status of the following clinical trial:

Trial Title: A Study of Telitacicept for Injection (RC18) in Subjects With IgA Nephropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. IgA nephropathy confirmed by pathological biopsy;~2. Male or female aged ≥ 18 years old;~3. Average 24-hour urine total protein ≥ 0.75 g/24 h~4. Estimated GFR (using the CKD-EPI formula) \> 30 mL/min per 1.73 m\^2;~5. Stabilized AEI/ARB medications, diuretics, or other antihypertensive therapy.~Exclusion Criteria:~1. Patients with clinically significant abnormal laboratory tests at screening;~2. Evidence of rapid eGFR decrease \> 15 ml/min during screening;~3. Renal or other organ transplantation prior to, or expected during, the study;~4. Patients with secondary IgA nephropathy;~5. Patients with nephrotic syndrome, crescentic nephritis minimal change nephropathy with IgA deposition, or other pathological or clinical types of renal diseases that may confound the study data interpretation;~6. Patients with history of any severe unstable cardiovascular and cerebrovascular events within 12 weeks prior to screening;~7. Immunocompromised individuals.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Telitacicept 160mg (Type: EXPERIMENTAL): Telitacicept 160mg subcutaneous injection once weekly, and a total of 24 doses
- Telitacicept 240mg (Type: EXPERIMENTAL): Telitacicept 240mg subcutaneous injection once weekly, and a total of 24 doses
- Placebo (Type: PLACEBO_COMPARATOR): Placebo subcutaneous injection once weekly, and a total of 24 doses

Based on this trial design, predict the completion outcome and termination type (if applicable).